CHRONOS3: Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to collect some parameters which may help to provide guidance on how Androgen Deprivation Therapy (ADT) drugs are renewed and physician satisfaction.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Prostate cancer patients Patients recently diagnosed with prostate cancer requiring ADT. |
Drug: triptorelin
This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Percentage of patients for whom the initial Gonadotropin-releasing Hormone (GnRH) analogue formulation has been renewed. [1 month]
To evaluate the percentage of patients for whom the initial GnRH analogue formulation has been renewed at 1-month +/- 7 days for Diphereline 3.75mg.
- Percentage of patients for whom the initial GnRH analogue formulation has been renewed. [3 months]
To evaluate the percentage of patients for whom the initial GnRH analogue formulation has been renewed at at 3-months +/- 10 days for Diphereline PR 11.25mg (Visit 2).
Secondary Outcome Measures
- Percentage of patients for whom the initial GnRH analogue formulation has been renewed at each follow up visit [6 and 12 months]
To evaluate the percentage of patients for whom the initial GnRH formulation (triptorelin-Diphereline®) had been renewed at each follow up visit [Visit 3 (at 6-months +/- 3 weeks), Visit 4 (at 12-months +/- 6 weeks)].
- Percentage of patients that switched from a 1-month to a 3-months formulation [3, 6, 12 months]
To evaluate the percentage of patients having switched from a 1-month to a 3-months formulation at each visit [Visit 2 (at 1 month or 3 months), Visit 3 (at 6 months +/- 3 weeks), Visit 4 (at 12 months +/- 6 weeks)].
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult men, ≥18 years old, with recently diagnosed locally advanced or metastatic prostate cancer scheduled to receive androgen deprivation therapy as monotherapy or as concomitant and adjuvant therapy in association with radiation therapy, with a 1 or 3 month GnRH analogue triptorelin formulation
-
Expected survival > 12 months.
-
Patients having provided written informed consent.
-
Patients mentally fit for completing a questionnaire.
Exclusion Criteria:
-
Treatment with any investigational drug within the last 3 months before study entry or planning to participate in a study.
-
Patients who already have been treated with a GnRH analogue within the last year.
-
Patients with hypersensitivity to GnRH, GnRH analogue, triptorelin or its excipients.
-
Patients with a contraindication according to SmPC.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Arad | Romania | |||
| 2 | Bucharest | Romania | |||
| 3 | Cluj-Napoca | Romania | |||
| 4 | Constanta | Romania | |||
| 5 | Craiova | Romania | |||
| 6 | Iasi | Romania | |||
| 7 | Timisoara | Romania |
Sponsors and Collaborators
- Ipsen
Investigators
- Study Director: Ipsen Medical Director, Ipsen
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- A-38-52014-213